ES2069894T3 - Una preparacion anticoagulante. - Google Patents

Una preparacion anticoagulante.

Info

Publication number
ES2069894T3
ES2069894T3 ES91912208T ES91912208T ES2069894T3 ES 2069894 T3 ES2069894 T3 ES 2069894T3 ES 91912208 T ES91912208 T ES 91912208T ES 91912208 T ES91912208 T ES 91912208T ES 2069894 T3 ES2069894 T3 ES 2069894T3
Authority
ES
Spain
Prior art keywords
epi
anticoagulant preparation
anticoagulant
preparation
mucopolisacaride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91912208T
Other languages
English (en)
Inventor
Ole Juul Nordfang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Application granted granted Critical
Publication of ES2069894T3 publication Critical patent/ES2069894T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Shaping By String And By Release Of Stress In Plastics And The Like (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Materials For Medical Uses (AREA)

Abstract

PARA LA PROFILAXIS O EL TRATAMIENTO DE ENFERMEDADES DE LA COAGULACION O DEL CANCER SE ADMINISTRA UN INHIBIDOR DE LA LINEA EXTRINSICA (EPI) JUNTO CON HEPARINA U OTRO MUCOPOLISACARIDO AL PACIENTE. DE ESTA FORMA SE OBTIENE UNA ACTIVIDAD COAGULANTE INCREMENTADA ASI COMO UN INCREMENTO DE LA VIDA MEDIA DEL EPI INYECTADO EN EL PLASMA.
ES91912208T 1990-06-19 1991-05-30 Una preparacion anticoagulante. Expired - Lifetime ES2069894T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK148890A DK148890D0 (da) 1990-06-19 1990-06-19 Farmaceutisk praeparat

Publications (1)

Publication Number Publication Date
ES2069894T3 true ES2069894T3 (es) 1995-05-16

Family

ID=8105367

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91912208T Expired - Lifetime ES2069894T3 (es) 1990-06-19 1991-05-30 Una preparacion anticoagulante.

Country Status (11)

Country Link
EP (1) EP0535129B1 (es)
JP (1) JP3362038B2 (es)
AT (1) ATE119781T1 (es)
AU (1) AU645581B2 (es)
BG (1) BG61181B1 (es)
CA (1) CA2085101A1 (es)
DE (1) DE69108242T2 (es)
DK (2) DK148890D0 (es)
ES (1) ES2069894T3 (es)
HU (1) HU221323B1 (es)
WO (1) WO1991019514A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291427B1 (en) 1990-08-27 2001-09-18 G.D. Searle & Co. Anticoagulant combination of LACI and sulfated polysaccharides
US5849703A (en) * 1990-08-27 1998-12-15 G. D. Searle & Co. Pre-formed anticoagulant heparin/TFPI complexes
DK261490D0 (da) * 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
US5276015A (en) * 1992-03-18 1994-01-04 Washington University Method of inhibiting microvascular thrombosis
US20030171292A1 (en) 1992-06-01 2003-09-11 Creasey Abla A. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US6063764A (en) * 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
KR950701820A (ko) * 1992-06-11 1995-05-17 로저 에이. 윌리암스 패혈증 및 패혈증-연관 옹고장애의 예방 및 치료(prophylaxs and treatment of sepsis and sepsis-associated coagulation disorders)
ZA941414B (en) * 1993-03-02 1994-09-28 Novo Nordisk A G Non-glycosylated TFPI analogues
US5981471A (en) * 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
EA200400548A1 (ru) 2001-10-15 2005-06-30 Чирон Корпорейшн Лечение тяжёлой пневмонии путём введения ингибитора пути тканевого фактора (tfpi)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3170001D1 (en) * 1980-09-30 1985-05-23 Bayer Ag Method for the production of an antithrombin-heparin complex and pharmaceutical compositions containing the complex
US4689323A (en) * 1983-09-26 1987-08-25 Miles Laboratories, Inc. Covalently bound heparin--antithrombin-III complex
IL79255A0 (en) * 1986-06-26 1986-09-30 Hadassah Med Org Composition for metastasis prevention
US4900723A (en) * 1988-04-29 1990-02-13 E. R. Squibb & Sons, Inc. Method of preventing or reducing venous thrombosis using a thromboxane A2 receptor antagonist in conjunction with heparin and combination
DK408089D0 (da) * 1989-08-18 1989-08-18 Novo Nordisk As Proteiner

Also Published As

Publication number Publication date
CA2085101A1 (en) 1991-12-20
AU8060491A (en) 1992-01-07
ATE119781T1 (de) 1995-04-15
WO1991019514A1 (en) 1991-12-26
HUT63578A (en) 1993-09-28
EP0535129A1 (en) 1993-04-07
AU645581B2 (en) 1994-01-20
HU221323B1 (en) 2002-09-28
DK148890D0 (da) 1990-06-19
BG97199A (bg) 1993-12-24
JP3362038B2 (ja) 2003-01-07
BG61181B1 (bg) 1997-02-28
DE69108242D1 (de) 1995-04-20
DE69108242T2 (de) 1995-07-06
DK0535129T3 (da) 1995-08-07
HU9204036D0 (en) 1993-03-29
EP0535129B1 (en) 1995-03-15
JPH05507926A (ja) 1993-11-11

Similar Documents

Publication Publication Date Title
UY28081A1 (es) Administracinn combinada de una indolinona con un agente quimioterapcutico para trastornos de proliferacinn celular
ES2069894T3 (es) Una preparacion anticoagulante.
BRPI0415533A (pt) método de terapia
DK1267897T3 (da) Behandling af kongestiv hjerteinsuffiens med forbehandlet autologt blod
BR9910251A (pt) Estimulação hematopoiética
ES2007607A6 (es) Un procedimiento para la obtencion de un preparado de insulina para la administracion no parenteral.
ATE312635T1 (de) Ventilanordnung
ES2080837T3 (es) Tratamiento de estados y enfermedades.
CY1116164T1 (el) Προδρομη 4-σουλφαταση ν-ακετυλογαλακτο σαμινης, μεθοδοι θεραπευτικης αγωγης που χρησιμοποιουν το εν λογω ενζυμο και μεθοδοι για παραγωγη και καθαρισμο του εν λογω ενζυμου
HUP9900681A2 (hu) TH1/TH2-citokinexpresszió modulálása Ribavirinnel és Ribavirin-analógokkal, aktivált T-limfocitákban
ES2060942T3 (es) Terapia genetica utilizando celulas estromicas.
ATE311191T1 (de) Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
ES2107414T3 (es) Utilizacion de interferon-beta humano para la estimulacion de la eritropoyesis.
ES2055314T3 (es) Tratamiento de disfuncion leucocitaria con gm-csf.
CL2022002239A1 (es) Tafoxiparina para el tratamiento de la preeclampsia
CL2022002104A1 (es) Tratamiento de infección por coronavirus con interferón lambda
ES2036560T3 (es) Un metodo para preparar una composicion sinergicamente activa para el tratamiento de hipertension.
ES2121617T3 (es) Derivados de 3-alcoxibencilpiperidinas como agentes melatonergicos.
Klein The mechanism of the virucidal action of ascorbic acid
SE0301577D0 (sv) Low sodium solution
CY1114254T1 (el) Ενδοφλεβια ενεση μη νευροτοξικων ενεργοποιητων του πλασμινογονου για την αντιμετωπιση του εγκεφαλικου επεισοδιου
WO2023081801A3 (en) Methods of treating sickle cell disease with voxelotor
ATE458495T1 (de) Therapeutische zubereitung für autoimmune erkrankungen
Tocantins et al. Increased plasma prothrombin activity after epinephrine injections; relation to hyperglycemia
Tiwari et al. A novel technique for piercing of ear lobule suited to Indian subcontinent

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 535129

Country of ref document: ES